Author:
Versluis Jurjen,Cornelissen Jan J.,Craddock Charles,Sanz Miguel Á.,Nagler Arnon
Abstract
AbstractAML is a malignancy of hematopoietic immature precursors (myeloblasts) that accumulate in the BM at the expense of their normal counterparts. AML is increasingly being recognized as a heterogenous malignancy based on distinct disease biology and underlying cytogenetic and molecular profiles. These profiles and measurable residual disease after induction therapy direct post-remission strategies in a risk-adapated approach, which also includes the assessment of the risk of treatment-related mortality. In primary refractory AML, allo-HSCT remains a curative treatment option in fit patients. Allo-HSCT in acute promyelocytic leukemia is only recommended for specific cases, particularly when not in moleculair remission after treatment for first relapse.
Publisher
Springer International Publishing
Reference73 articles.
1. Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129:1275–83.
2. Abhishek M, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021;5(7):1876–83.
3. Alimoghaddam K, Ghavamzadeh A, Jahani M, et al. Hematopoietic stem cell transplantation in acute promyelocytic leukemia, experience in Iran. Arch Iran Med. 2011;14:332–4.
4. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96.
5. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, Wang SA, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28.